0001209191-23-058774.txt : 20231215
0001209191-23-058774.hdr.sgml : 20231215
20231215162326
ACCESSION NUMBER: 0001209191-23-058774
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231213
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SIEGALL CLAY B
CENTRAL INDEX KEY: 0001167496
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 231490682
MAIL ADDRESS:
STREET 1: 21823 30TH DR SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tourmaline Bio, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-481-9832
MAIL ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: Talaris Therapeutics, Inc.
DATE OF NAME CHANGE: 20201007
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-13
0
0001827506
Tourmaline Bio, Inc.
TRML
0001167496
SIEGALL CLAY B
C/O TOURMALINE BIO, INC.
27 WEST 24TH STREET, SUITE 702
NEW YORK
NY
10010
1
0
0
0
0
Stock Option (Right to Buy)
18.55
2023-12-13
4
A
0
20000
0.00
A
2033-12-12
Common Stock
20000
20000
D
The shares subject to the option shall vest and become exercisable in thirty-six (36) equal monthly installments beginning on January 13, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
/s/ Brad Middlekauff, Attorney-in-Fact
2023-12-15